ImmunityBio, NantKwest dose first patient in novel Covid-19 vaccine candidate trial

ImmunityBio and NantKwest have dosed a first patient in the phase I clinical study of novel Covid-19 vaccine candidate called hAd5-Covid-19.

Read the full article here

Related Articles